Search General Info
Search Education
Search Partnering Companies
![BIF](/sites/default/files/2023-05/230112-bio-bif-logo-color-horiz.jpg)
2020 BIO Investor Forum Buzz of BIO Winner
Stella Diagnostics, Inc. is a molecular diagnostics-based organization focused on improving patient management strategies for over 67 million people living with severe esophageal disease. StellaDX’s mass spectroscopy-based proteomic assay, STLA101, offers physicians insight into the molecular properties of their patients’ tissue to determine if the disease is stable, progressing or turning cancerous. STLA101 aims to be a first-line diagnostic tool that provides more robust molecular data of diseased esophageal tissue compared to the current standard of care. Using targeted mass spectrometry proteomics, we believe that informing physicians of the expression patterns playing a role in the pathogenesis of GERD, Barrett's esophagus and esophageal cancer early in the treatment plan may extend or save lives.
Stella Diagnostics, Inc. is a molecular diagnostics-based organization focused on improving patient management strategies for over 67 million people living with severe esophageal disease. StellaDX’s mass spectroscopy-based proteomic assay, STLA101, offers physicians insight into the molecular properties of their patients’ tissue to determine if the disease is stable, progressing or turning cancerous. STLA101 aims to be a first-line diagnostic tool that provides more robust molecular data of diseased esophageal tissue compared to the current standard of care. Using targeted mass spectrometry proteomics, we believe that informing physicians of the expression patterns playing a role in the pathogenesis of GERD, Barrett's esophagus and esophageal cancer early in the treatment plan may extend or save lives.
![](/sites/default/files/hubb_images/2996/attachments/%2520-%2520f1_Stella_20Diagnostics_2C_20Inc__4549fcb7.jpg)
Ticker:
JMDP (name change to STLA processing)
Exchange:
OTC
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2020
Main Therapeutic Focus:
Diagnostics
Lead Product in Development:
STLA101
Development Phase of Primary Product:
Discovery
Number Of Unlicensed Products (For Which You Are Seeking Partners):
4
Speaker
![photo](/sites/default/files/hubb_images/2996/photos/user1.Abdo.403ac8fd.png)
Biotechnology Innovation Organization
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2024 All Rights Reserved